FAQ Library

When is it appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of HL?

FAQ published on June 1, 2016

In this Managing Hodgkin Lymphoma FAQ, join Dr. Andrew Evens as he explains when it is appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of Hodgkin lymphoma (HL).

Which factors are more important when developing treatment plans for the newly diagnosed HL patient?

Andrew Evens, DO, MSc, FACP

FAQ published on May 4, 2016

In this Managing Hodgkin Lymphoma FAQ, join Dr. Andrew Evens as he explains the top three factors that impact the development of treatment plans for newly diagnosed HL patients.

Is there a changing paradigm in the management of patients with relapsed or refractory HL?

Robert W. Chen, MD

FAQ published on April 5, 2016

Join Dr. Robert Chen as he discusses the change in the treatment paradigm for patients with relapsed or refractory Hodgkin lymphoma in recent years.

What alternatives may be used to accurately stage Hodgkin lymphoma if PET-CT is not available?

Bruce D. Cheson, MD

FAQ published on March 3, 2016

Join Bruce D. Cheson, MD, in this Managing HL FAQ as he explains the alternatives that may be used to accurately stage Hodgkin lymphoma if a PET-CT is not available.

Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?

Bruce D. Cheson, MD

FAQ published on February 3, 2016

Join Bruce D. Cheson, MD, in this Managing HL FAQ as he explains whether or not CD30 is an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma.

What strategies can be utilized to accurately diagnose Hodgkin lymphoma in areas that lack adequate pathology?

Bruce D. Cheson, MD

FAQ published on January 11, 2016

Join Bruce D. Cheson, MD, in this Managing HL FAQ as he describes the strategies that can be utilized to accurately diagnose Hodgkin lymphoma in areas that lack adequate pathology.

What are the key issues in the NCCN Guidelines related to imaging patients with HL?

Richard Hoppe, MD

FAQ published on August 12, 2015

Dr. Richard Hoppe explains the key issues in the NCCN Guidelines related to imaging patients with Hodgkin lymphoma.

Do you believe the updated Lugano Classification System for Hodgkin and Non-Hodgkin Lymphomas will lead to substantial change in how clinicians practice today?

Richard Hoppe, MD

FAQ published on August 12, 2015

Dr. Richard Hoppe discusses the impact of the updated Lugano Classification System for Hodgkin and Non-Hodgkin Lymphomas on today's practicing clinicians.

What are the important conclusions that practicing clinicians should be aware of in regards to the recent NCCN guidelines in HL?

Richard Hoppe, MD

FAQ published on August 3, 2015

Dr. Richard Hoppe discusses the important conclusions practicing clinicians should be aware of in regards to the recently published NCCN Hodgkin Lymphoma Guidelines.

What are the most significant updates to the recently published NCCN HL Guidelines?

Richard Hoppe, MD

FAQ published on August 3, 2015

Dr. Richard Hoppe discusses the most significant updates to the recently published NCCN Hodgkin Lymphoma Guidelines.

FAQ

MediCom Worldwide, Inc. Links